J9063 Mirvetuximab soravtansine - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Mirvetuximab soravtansine

Brand Name:

Elahere

Strength:

1mg

HCPCS:

J9063

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

FR-alpha, DM4

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

July 11, 2023

CMS Discontinuation Date:

Status:

In Use